{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:49:09Z","timestamp":1792799349223,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81822016"],"award-info":[{"award-number":["No. 81822016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81771382"],"award-info":[{"award-number":["No. 81771382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81901090"],"award-info":[{"award-number":["No. 81901090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The pathologic accumulation and aggregation of tau is a hallmark of tauopathies including Alzheimer\u2019s disease (AD). However, the molecular mechanisms mediating tau aggregation in AD remain elusive. The incidence of AD is increased in patients with type 2 diabetes (T2DM), which is characterized by the amyloid deposition of islet amyloid polypeptide (IAPP) in the pancreas. However, the molecular mechanisms bridging AD and T2DM remain unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We first examined the presence of IAPP in the neurofibrillary tangles of AD patients. Then we tested the effect of IAPP on tau aggregation. The biochemical and biological characteristics of the IAPP-tau fibrils were tested in vitro. The seeding activity and neurotoxicity of the IAPP-tau fibrils were confirmed in cultured neurons. Lastly, the effect of IAPP on tau pathology and cognitive impairments was determined by injecting the IAPP-tau fibrils and IAPP fibrils into the hippocampus of tau P301S mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that IAPP interacts with tau and accelerates the formation of a more toxic strain, which shows distinct morphology with enhanced seeding activity and neurotoxicity in vitro. Intrahippocampal injection of the IAPP-tau strain into the tau P301S transgenic mice substantially promoted the spreading of tau pathology and induced more severe synapse loss and cognitive deficits, when compared with tau fibrils. Furthermore, intracerebral injection of synthetic IAPP fibrils initiated tauopathy in the brain of tau P301S transgenic mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These observations indicate that IAPP acts as a crucial mediator of tau pathology in AD, and provide a mechanistic explanation for the higher risk of AD in individuals with T2DM.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13024-022-00518-y","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:03:03Z","timestamp":1643457783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Guoxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanxia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-1472","authenticated-orcid":false,"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"518_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","volume":"16","author":"C Peng","year":"2020","unstructured":"Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat Rev Neurol. 2020;16:199\u2013212.","journal-title":"Nat Rev Neurol"},{"key":"518_CR2","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1523\/JNEUROSCI.1230-17.2017","volume":"37","author":"S Narasimhan","year":"2017","unstructured":"Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV, et al. Pathological tau strains from human brains recapitulate the diversity of Tauopathies in nontransgenic mouse Brain. J Neurosci. 2017;37:11406\u201323.","journal-title":"J Neurosci"},{"key":"518_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.neuron.2016.09.055","volume":"92","author":"SK Kaufman","year":"2016","unstructured":"Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, et al. Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron. 2016;92:796\u2013812.","journal-title":"Neuron"},{"key":"518_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","volume":"5","author":"GJ Biessels","year":"2006","unstructured":"Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64\u201374.","journal-title":"Lancet Neurol"},{"key":"518_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","volume":"53","author":"J Janson","year":"2004","unstructured":"Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474\u201381.","journal-title":"Diabetes"},{"key":"518_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","volume":"53","author":"A Ott","year":"1999","unstructured":"Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999;53:1937\u201342.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"518_CR7","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.3233\/JAD-2012-111433","volume":"30","author":"JA Luchsinger","year":"2012","unstructured":"Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis. 2012;30(Suppl 2):S185\u201398.","journal-title":"J Alzheimers Dis"},{"key":"518_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1192\/bjp.bp.109.067942","volume":"196","author":"L Velayudhan","year":"2010","unstructured":"Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry. 2010;196:36\u201340.","journal-title":"Br J Psychiatry"},{"key":"518_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.neurobiolaging.2013.09.033","volume":"35","author":"JK Morris","year":"2014","unstructured":"Morris JK, Vidoni ED, Honea RA, Burns JM. Alzheimer's disease neuroimaging I: impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging. 2014;35:585\u20139.","journal-title":"Neurobiol Aging"},{"key":"518_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795\u2013826.","journal-title":"Physiol Rev"},{"key":"518_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/BF03402051","volume":"6","author":"GT Westermark","year":"2000","unstructured":"Westermark GT, Gebre-Medhin S, Steiner DF, Westermark P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med. 2000;6:998\u20131007.","journal-title":"Mol Med"},{"key":"518_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJM200008103430607","volume":"343","author":"JW Hoppener","year":"2000","unstructured":"Hoppener JW, Ahren B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med. 2000;343:411\u20139.","journal-title":"N Engl J Med"},{"key":"518_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2015.04.005","volume":"21","author":"A Mukherjee","year":"2015","unstructured":"Mukherjee A, Morales-Scheihing D, Butler PC, Soto C. Type 2 diabetes as a protein misfolding disease. Trends Mol Med. 2015;21:439\u201349.","journal-title":"Trends Mol Med"},{"key":"518_CR14","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281\u20139.","journal-title":"J Neurosci"},{"key":"518_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129:729\u201348.","journal-title":"Acta Neuropathol"},{"key":"518_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1021\/acschemneuro.7b00396","volume":"9","author":"X Ge","year":"2018","unstructured":"Ge X, Yang Y, Sun Y, Cao W, Ding F. Islet amyloid polypeptide promotes amyloid-Beta aggregation by binding-induced Helix-unfolding of the Amyloidogenic Core. ACS Chem Neurosci. 2018;9:967\u201375.","journal-title":"ACS Chem Neurosci"},{"key":"518_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hipo.22837","volume":"28","author":"T Li","year":"2018","unstructured":"Li T, Jiao JJ, Holscher C, Wu MN, Zhang J, Tong JQ, et al. A novel GLP-1\/GIP\/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. Hippocampus. 2018;28:358\u201372.","journal-title":"Hippocampus"},{"key":"518_CR18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2174\/1567205011666141107124538","volume":"11","author":"JN Fawver","year":"2014","unstructured":"Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, et al. Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer's disease. Curr Alzheimer Res. 2014;11:928\u201340.","journal-title":"Curr Alzheimer Res"},{"key":"518_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10495-011-0656-3","volume":"17","author":"JH Jhamandas","year":"2012","unstructured":"Jhamandas JH, Mactavish D. beta-amyloid protein (Abeta) and human amylin regulation of apoptotic genes occurs through the amylin receptor. Apoptosis. 2012;17:37\u201347.","journal-title":"Apoptosis"},{"key":"518_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ana.23956","volume":"74","author":"K Jackson","year":"2013","unstructured":"Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann Neurol. 2013;74:517\u201326.","journal-title":"Ann Neurol"},{"key":"518_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.neurobiolaging.2008.08.019","volume":"31","author":"J Miklossy","year":"2010","unstructured":"Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F, et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010;31:1503\u201315.","journal-title":"Neurobiol Aging"},{"key":"518_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neurobiolaging.2018.05.003","volume":"69","author":"N Schultz","year":"2018","unstructured":"Schultz N, Byman E, Netherlands Brain B, Wennstrom M. Levels of retinal IAPP are altered in Alzheimer's disease patients and correlate with vascular changes and hippocampal IAPP levels. Neurobiol Aging. 2018;69:94\u2013101.","journal-title":"Neurobiol Aging"},{"key":"518_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/anie.201105877","volume":"51","author":"J Seeliger","year":"2012","unstructured":"Seeliger J, Evers F, Jeworrek C, Kapoor S, Weise K, Andreetto E, et al. Cross-amyloid interaction of Abeta and IAPP at lipid membranes. Angew Chem Int Ed Engl. 2012;51:679\u201383.","journal-title":"Angew Chem Int Ed Engl"},{"key":"518_CR24","doi-asserted-by":"crossref","unstructured":"Kam TI, Mao X, Park H, Chou SC, Karuppagounder SS, Umanah GE, et al. Poly (ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson's disease. Science. 2018;362(6414):eaat8407.","DOI":"10.1126\/science.aat8407"},{"key":"518_CR25","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med. 2014;20:1254\u201362.","journal-title":"Nat Med"},{"key":"518_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nn.3648","volume":"17","author":"E Aarts","year":"2014","unstructured":"Aarts E, Verhage M, Veenvliet JV, Dolan CV, van der Sluis S. A solution to dependency: using multilevel analysis to accommodate nested data. Nat Neurosci. 2014;17:491\u20136.","journal-title":"Nat Neurosci"},{"key":"518_CR27","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbamem.2018.02.020","volume":"1860","author":"S Asthana","year":"2018","unstructured":"Asthana S, Mallick B, Alexandrescu AT, Jha S. IAPP in type II diabetes: basic research on structure, molecular interactions, and disease mechanisms suggests potential intervention strategies. Biochim Biophys Acta Biomembr. 2018;1860:1765\u201382.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"518_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-4-48","volume":"4","author":"GM Shankar","year":"2009","unstructured":"Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener. 2009;4:48.","journal-title":"Mol Neurodegener"},{"key":"518_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41594-020-0442-4","volume":"27","author":"C Roder","year":"2020","unstructured":"Roder C, Kupreichyk T, Gremer L, Schafer LU, Pothula KR, Ravelli RBG, et al. Cryo-EM structure of islet amyloid polypeptide fibrils reveals similarities with amyloid-beta fibrils. Nat Struct Mol Biol. 2020;27:660\u20137.","journal-title":"Nat Struct Mol Biol"},{"key":"518_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s41594-020-0435-3","volume":"27","author":"Q Cao","year":"2020","unstructured":"Cao Q, Boyer DR, Sawaya MR, Ge P, Eisenberg DS. Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrils. Nat Struct Mol Biol. 2020;27:653\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"518_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41594-020-0496-3","volume":"27","author":"R Gallardo","year":"2020","unstructured":"Gallardo R, Iadanza MG, Xu Y, Heath GR, Foster R, Radford SE, et al. Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly. Nat Struct Mol Biol. 2020;27:1048\u201356.","journal-title":"Nat Struct Mol Biol"},{"key":"518_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajpath.2014.11.016","volume":"185","author":"ME Oskarsson","year":"2015","unstructured":"Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol. 2015;185:834\u201346.","journal-title":"Am J Pathol"},{"key":"518_CR33","doi-asserted-by":"crossref","first-page":"e12130","DOI":"10.1002\/trc2.12130","volume":"7","author":"H Ly","year":"2021","unstructured":"Ly H, Verma N, Sharma S, Kotiya D, Despa S, Abner EL, et al. The association of circulating amylin with beta-amyloid in familial Alzheimer's disease. Alzheimers Dement (N Y). 2021;7:e12130.","journal-title":"Alzheimers Dement (N Y)"},{"key":"518_CR34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","volume":"57","author":"WA Banks","year":"1995","unstructured":"Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci. 1995;57:1993\u20132001.","journal-title":"Life Sci"},{"key":"518_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt231","volume":"6","author":"ME Murray","year":"2014","unstructured":"Murray ME, Kouri N, Lin WL, Jack CR Jr, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther. 2014;6:1.","journal-title":"Alzheimers Res Ther"},{"key":"518_CR36","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1021\/bi400866w","volume":"52","author":"OA Morozova","year":"2013","unstructured":"Morozova OA, March ZM, Robinson AS, Colby DW. Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. Biochemistry. 2013;52:6960\u20137.","journal-title":"Biochemistry"},{"key":"518_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1176\/appi.ajp.2014.14070878","volume":"172","author":"C Cooper","year":"2015","unstructured":"Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:323\u201334.","journal-title":"Am J Psychiatry"},{"key":"518_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaneurol.2015.4899","volume":"73","author":"TP Ng","year":"2016","unstructured":"Ng TP, Feng L, Nyunt MS, Feng L, Gao Q, Lim ML, et al. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia: follow-up of the Singapore longitudinal ageing study cohort. JAMA Neurol. 2016;73:456\u201363.","journal-title":"JAMA Neurol"},{"key":"518_CR39","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","volume":"5","author":"L Jia","year":"2020","unstructured":"Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5:e661\u201371.","journal-title":"Lancet Public Health"},{"key":"518_CR40","doi-asserted-by":"publisher","first-page":"e7917","DOI":"10.1371\/journal.pone.0007917","volume":"4","author":"YD Ke","year":"2009","unstructured":"Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One. 2009;4:e7917.","journal-title":"PLoS One"},{"key":"518_CR41","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1210\/en.2009-0695","volume":"150","author":"B Kim","year":"2009","unstructured":"Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009;150:5294\u2013301.","journal-title":"Endocrinology"},{"key":"518_CR42","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"L Escribano","year":"2010","unstructured":"Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010;35:1593\u2013604.","journal-title":"Neuropsychopharmacology"},{"key":"518_CR43","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"ME Risner","year":"2006","unstructured":"Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Rosiglitazone in Alzheimer's disease study G: efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6:246\u201354.","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"518_CR44","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1021\/acs.jnatprod.0c01162","volume":"84","author":"JY Hsu","year":"2021","unstructured":"Hsu JY, Rao Sathyan A, Hsu KC, Chen LC, Yen CC, Tseng HJ, et al. Synthesis of Yakuchinone B-inspired inhibitors against islet amyloid polypeptide aggregation. J Nat Prod. 2021;84(4):1096\u2013103.","journal-title":"J Nat Prod"},{"key":"518_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.trci.2016.11.005","volume":"3","author":"R Soudy","year":"2017","unstructured":"Soudy R, Patel A, Fu W, Kaur K, MacTavish D, Westaway D, et al. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's disease. Alzheimers Dement (N Y). 2017;3:44\u201356.","journal-title":"Alzheimers Dement (N Y)"},{"key":"518_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/mp.2014.17","volume":"20","author":"H Zhu","year":"2015","unstructured":"Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Mol Psychiatry. 2015;20:252\u201362.","journal-title":"Mol Psychiatry"},{"key":"518_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","volume":"35","author":"BL Adler","year":"2014","unstructured":"Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging. 2014;35:793\u2013801.","journal-title":"Neurobiol Aging"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00518-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00518-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T13:54:31Z","timestamp":1700142871000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00518-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00518-y","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"17 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals and experimental procedures were approved by the ethical committees of Renmin Hospital, Wuhan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}